The share price of Dynavax Technologies Corporation [NASDAQ: DVAX] inclined by $5.73, presently trading at $6.17. The company’s shares saw 137.76% gains compared to the lowest price in the period of the last 52 weeks, set at $2.60 recorded on Jan 16, 2020. The last few days have been benevolent to the share price as DVAX jumped by +4.75% during the last week, even though the stock is still down by -0.79% compared to 0.28 of all time high it touched on 01/16/20. However, the stock had a strong performance during the past 3 months, roughly losing -9.33%, while additionally dropping -48.63% during the last 12 months. Dynavax Technologies Corporation is said to have a 12-month price target set at $14.00. That means that the stock has a strong potential to acquire 7.83% increase from the current trading price.
Dynavax Technologies Corporation [NASDAQ:DVAX]: Analyst Rating and Earnings
Its stock price has been found in the range of 2.60 to 12.42. This is compared to its latest closing price of $5.73.
Pay attention to the next-scheduled financial results for this company to be released, which is slated for Tue 25 Feb (In 40 Days).
Fundamental Analysis of Dynavax Technologies Corporation [DVAX]
Now let’s turn to look at profitability: with a current Operating Margin for Dynavax Technologies Corporation [DVAX] sitting at -1836.14 and its Gross Margin at -210.04.
This company’s Return on Total Capital is -82.82, and its Return on Invested Capital has reached -93.50%. Its Return on Equity is -121.01, and its Return on Assets is -73.96. These metrics suggest that this Dynavax Technologies Corporation does a poor job of managing its assets, and likely won’t be able to provide successful business outcomes for its investors in the near term.
Turning to investigate this organization’s capital structure, Dynavax Technologies Corporation [DVAX] has generated a Total Debt to Total Equity ratio of 159.95. Similarly, its Total Debt to Total Capital is 61.53, while its Total Debt to Total Assets stands at 47.83. Looking toward the future, this publicly-traded company’s Long-Term Debt to Equity is -16.12, and its Long-Term Debt to Total Capital is 159.95.
What about valuation? This company’s Enterprise Value to EBITDA is -3.11. The Enterprise Value to Sales for this firm is now 14.10, and its Total Debt to Enterprise Value stands at 0.19. Dynavax Technologies Corporation [DVAX] has a Price to Book Ratio of 9.12.
Shifting the focus to workforce efficiency, Dynavax Technologies Corporation [DVAX] earns $32,924 for each employee under its payroll. Similarly, this company’s Receivables Turnover is 3.60 and its Total Asset Turnover is 0.04. This publicly-traded organization’s liquidity data is also interesting: its Quick Ratio is 4.08 and its Current Ratio is 4.58. This company, considering these metrics, has a healthy ratio between its short-term liquid assets and its short-term liabilities, making it a less risky investment.
Dynavax Technologies Corporation [DVAX] has 87.74M shares outstanding, amounting to a total market cap of $541.36M. Its stock price has been found in the range of 2.60 to 12.42. At its current price, it has moved down by -50.32% from its 52-week high, and it has moved up 137.76% from its 52-week low.
This stock’s Beta value is currently 0.61, which indicates that it is 6.72% more volatile that the wider market. This stock’s Relative Strength Index (RSI) is at 52.99. This RSI score is good, suggesting this stock is neither overbought or oversold.
Conclusion: Is Dynavax Technologies Corporation [DVAX] a Reliable Buy?
Shares of Dynavax Technologies Corporation [DVAX], on the whole, present investors with both positive and negative signals. Wall Street analysts have mixed reviews when it comes to the 12-month price outlook, and this company’s financials show a combination of strengths and weaknesses. Based on the price performance, this investment is somewhat risky while presenting reasonable potential for ROI.